Detalhe da pesquisa
1.
The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms.
J Clin Med
; 12(4)2023 Feb 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-36835891